iShares U.S. Pharmaceuticals ETF (IHE) Holdings
IHE holdings summary
as of Oct 25, 2026- Holdings
- 53 positions listed
- Top 10 weight
- 79.7% of net assets
- Effective holdings
- 8 equal-weight equivalent
- Largest holding
- LLY 25.36% Eli Lilly and Company
- Annual turnover
- 43.9% of the portfolio traded
All IHE holdings
| # | Name | ||||||
|---|---|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly and Company | Healthcare | 25.36% | $389.8M | $1.12T | 42.2 |
| 2 | JNJ | Johnson & Johnson | Healthcare | 21.68% | $333.2M | $615.87B | 38.8 |
| 3 | PFE | Pfizer Inc. | Healthcare | 4.92% | $75.6M | $168.60B | 38.9 |
| 4 | ZTS | Zoetis Inc. | Healthcare | 4.82% | $74.1M | $32.80B | 13.1 |
| 5 | VTRS | Viatris Inc. | Healthcare | 4.77% | $73.3M | $21.43B | — |
| 6 | RPRX | Royalty Pharma plc | Healthcare | 4.40% | $67.6M | $35.22B | 32.4 |
| 7 | MRK | Merck & Co., Inc. | Healthcare | 4.25% | $65.3M | $360.08B | 115.8 |
| 8 | BMY | Bristol-Myers Squibb Company | Healthcare | 4.14% | $63.6M | $122.05B | 13.2 |
| 9 | JAZZ | Jazz Pharmaceuticals plc | Healthcare | 2.93% | $45.0M | $13.65B | 14.4 |
| 10 | ELAN | Elanco Animal Health Incorporated | Healthcare | 2.42% | $37.2M | $11.76B | — |
| 11 | CORT | Corcept Therapeutics Incorporated | Healthcare | 2.27% | $34.8M | $11.91B | 244.8 |
| 12 | AXSM | Axsome Therapeutics, Inc. | Healthcare | 1.47% | $22.6M | $8.23B | — |
| 13 | LGND | Ligand Pharmaceuticals Incorporated | Healthcare | 1.34% | $20.6M | $5.89B | 31.1 |
| 14 | DFTX | Definium Therapeutics, Inc. | Healthcare | 1.08% | $16.5M | $4.31B | — |
| 15 | MANE | Veradermics, Incorporated | Healthcare | 0.97% | $14.9M | $4.55B | — |
| 16 | INDV | Indivior PLC | Healthcare | 0.86% | $13.3M | $3.83B | 11.6 |
| 17 | AMRX | Amneal Pharmaceuticals, Inc. | Healthcare | 0.84% | $13.0M | $6.68B | 39.1 |
| 18 | OGN | Organon & Co. | Healthcare | 0.78% | $12.0M | $3.61B | 17.6 |
| 19 | EWTX | Edgewise Therapeutics, Inc. | Healthcare | 0.72% | $11.0M | $4.04B | — |
| 20 | AMLX | Amylyx Pharmaceuticals, Inc. | Healthcare | 0.62% | $9.6M | $3.31B | — |
| 21 | LQDA | Liquidia Corporation | Healthcare | 0.61% | $9.4M | $3.07B | 24.7 |
| 22 | ELVN | Enliven Therapeutics, Inc. | Healthcare | 0.59% | $9.1M | $2.73B | — |
| 23 | TARS | Tarsus Pharmaceuticals, Inc. | Healthcare | 0.57% | $8.8M | $3.19B | — |
| 24 | SUPN | Supernus Pharmaceuticals, Inc. | Healthcare | 0.54% | $8.3M | $2.21B | — |
| 25 | PRGO | Perrigo Company plc | Healthcare | 0.50% | $7.8M | $2.30B | — |
| 26 | PBH | Prestige Consumer Healthcare Inc. | Healthcare | 0.49% | $7.5M | $2.36B | 14.0 |
| 27 | XERS | Xeris Biopharma Holdings, Inc. | Healthcare | 0.44% | $6.8M | $1.88B | — |
| 28 | HRMY | Harmony Biosciences Holdings, Inc. | Healthcare | 0.38% | $5.9M | $2.21B | 12.2 |
| 29 | ANIP | ANI Pharmaceuticals, Inc. | Healthcare | 0.33% | $5.1M | $1.66B | 15.6 |
| 30 | TRVI | Trevi Therapeutics, Inc. | Healthcare | 0.33% | $5.0M | $1.69B | — |
| 31 | MBX | MBX Biosciences, Inc. | Healthcare | 0.32% | $4.9M | $2.39B | — |
| 32 | INVA | Innoviva, Inc. | Healthcare | 0.31% | $4.8M | $1.50B | 4.9 |
| 33 | PCRX | Pacira BioSciences, Inc. | Healthcare | 0.30% | $4.6M | $1.45B | 103.8 |
| 34 | OCUL | Ocular Therapeutix, Inc. | Healthcare | 0.27% | $4.2M | $1.51B | — |
| 35 | OMER | Omeros Corporation | Healthcare | 0.27% | $4.1M | $1.17B | 13.3 |
| 36 | NUVB | Nuvation Bio Inc. | Healthcare | 0.26% | $4.1M | $1.56B | — |
| 37 | MAZE | Maze Therapeutics, Inc. | Healthcare | 0.24% | $3.7M | $1.53B | — |
| 38 | SEPN | Septerna, Inc. | Healthcare | 0.21% | $3.3M | $1.70B | — |
| 39 | LBRX | LB Pharmaceuticals Inc | Healthcare | 0.21% | $3.2M | $1.19B | 367.4 |
| 40 | RAPP | Rapport Therapeutics, Inc. | Healthcare | 0.19% | $3.0M | $1.32B | — |
| 41 | PAHC | Phibro Animal Health Corporation | Healthcare | 0.19% | $2.9M | $1.58B | 16.0 |
| 42 | HROW | Harrow Health, Inc. | Healthcare | 0.18% | $2.8M | $1.02B | — |
| 43 | AMPH | Amphastar Pharmaceuticals, Inc. | Healthcare | 0.18% | $2.8M | $1.10B | 15.3 |
| 44 | COLL | Collegium Pharmaceutical, Inc. | Healthcare | 0.16% | $2.4M | $755.0M | 18.3 |
| 45 | ALMS | Alumis Inc. | Healthcare | 0.13% | $2.1M | $792.1M | — |
| 46 | CRMD | CorMedix Inc. | Healthcare | 0.12% | $1.8M | $565.9M | 3.5 |
| 47 | WVE | Wave Life Sciences Ltd. | Healthcare | 0.11% | $1.6M | $616.8M | — |
| 48 | AVLN | Avalyn Pharma Inc. | Healthcare | 0.11% | $1.6M | $1.05B | — |
| 49 | ARVN | Arvinas, Inc. | Healthcare | 0.10% | $1.5M | $449.7M | 26.8 |
| 50 | EOLS | Evolus, Inc. | Healthcare | 0.09% | $1.4M | $469.0M | — |
| 51 | PHAT | Phathom Pharmaceuticals, Inc. | Healthcare | 0.09% | $1.3M | $559.8M | — |
| 52 | BIOA | BioAge Labs, Inc | Healthcare | 0.04% | $688,668.82 | $222.1M | — |
| 53 | EYPT | EyePoint Pharmaceuticals, Inc. | Healthcare | 0.01% | $126,050.99 | $250.7M | — |
Weights as a percentage of net assets. Value held = weight × net assets ($1.54B). Market cap and P/E from each company's latest fundamentals (U.S.-listed stocks).
IHE sector breakdown
Sum of the weights of the holdings in each sector.
IHE top industries
IHE overlap with other ETFs
| ETF | Fund | Overlap | Shared holdings | Expense ratio |
|---|---|---|---|---|
| DIA | SPDR Dow Jones Industrial Average ETF | 4.8% | 2 of 30 | 0.16% |
| SPY | SPDR S&P 500 ETF | 3.4% | 7 of 502 | 0.09% |
| VTI | Vanguard Total Stock Market ETF | 3.3% | 50 of 2,941 | 0.03% |
| IWM | iShares Russell 2000 ETF | 2.3% | 40 of 1,962 | 0.19% |
| VXUS | Vanguard Total International Stock ETF | 0.0% | 1 of 8,035 | 0.05% |
| QQQ | Invesco QQQ ETF | 0.0% | 0 of 101 | 0.17% |
Overlap = sum over shared holdings of the smaller of the two weights. 100% means identical portfolios.
About the IHE portfolio
iShares U.S. Pharmaceuticals ETF holds 53 positions. The ten largest make up 79.7% of the fund and the top 50 99.4%, so it behaves like a portfolio of about 8 equally weighted stocks. The biggest positions are Eli Lilly and Company (25.36%), Johnson & Johnson (21.68%), Pfizer Inc. (4.92%), Zoetis Inc. (4.82%), Viatris Inc. (4.77%).
By sector, Healthcare is 99.5%. Holdings data is from the fund's latest portfolio as reported by EODHD on October 25, 2026; positions change as the fund rebalances.
Related: IHE chart, IHE performance, IHE dividends, IHE valuation, IHE overview.
IHE holdings FAQ
How many holdings does IHE have?
IHE holds 53 positions as of October 25, 2026.
What are the top 10 holdings of IHE?
The ten largest holdings are Eli Lilly and Company (25.36%), Johnson & Johnson (21.68%), Pfizer Inc. (4.92%), Zoetis Inc. (4.82%), Viatris Inc. (4.77%), Royalty Pharma plc (4.40%), Merck & Co., Inc. (4.25%), Bristol-Myers Squibb Company (4.14%), Jazz Pharmaceuticals plc (2.93%), Elanco Animal Health Incorporated (2.42%). Together they are 79.7% of the fund.
What percentage of IHE is Eli Lilly and Company?
Eli Lilly and Company is the largest holding at 25.36% of net assets, about $389.8M of the fund's $1.54B.
How concentrated is IHE?
The top 10 holdings are 79.7% of the fund. By the effective number of holdings (1 divided by the sum of squared weights) IHE behaves like a portfolio of about 8 equally weighted stocks.